LIXTE Biotechnology Updates on LB-100 Progress for Ovarian and Colorectal Cancer Treatment

LIXTE Biotechnology Holdings, Inc., an innovative pharmaceutical company listed on Nasdaq under the symbols LIXT and LIXTW, is making significant strides in cancer treatment. As a clinical-stage enterprise, LIXTE is focused on developing advanced cancer therapies that enhance the efficacy of chemotherapy and immunotherapy. Recently, LIXTE shared updates on its varied activities in the cancer research domain.

LIXTE is actively involved in collaborative clinical studies with two leading pharmaceutical entities to assess its proprietary compound, LB-100, in the treatment of ovarian and colorectal cancer. According to Bas van der Baan, the President and CEO of LIXTE, LB-100 has shown promising tolerance in patients with clear cell ovarian cancer at effective anti-cancer doses. This development aligns with LIXTE's mission to provide impactful solutions for cancer patients.

Clinical trials for ovarian cancer are currently underway at the M.D. Anderson Cancer Center and Northwestern University, with support from GSK. Concurrently, a colorectal cancer trial, supported by F. Hoffmann-La Roche, is being carried out at the Netherlands Cancer Institute. These trials mark significant milestones for LIXTE's research efforts. The initial patient dosing in a Phase 1b/2 trial combines LIXTE's LB-100 with GSK's immunotherapy, dostarlimab-gxly, targeting ovarian clear cell carcinoma. Additionally, LIXTE has initiated patient dosing in a new clinical trial in collaboration with the Netherlands Cancer Institute, supported by Roche, focusing on unresponsive metastatic colorectal cancer.

On the intellectual property front, LIXTE has strengthened its portfolio with the receipt of a Notice of Allowance from the United States Patent and Trademark Office for a patent application concerning "Oxabicycloheptanes for Modulation of Immune Response." This development includes combining LB-100 with various novel cancer immunotherapies, highlighting LIXTE's commitment to innovation in cancer treatment.

Financially, LIXTE successfully completed a registered direct offering, raising approximately $1,050,000. The funds are earmarked for working capital and general corporate purposes, supporting the company's ongoing research and development initiatives.

LIXTE's LB-100 compound has also garnered attention in the scientific community, with two pivotal studies published in renowned medical journals. A study in Cancer Discovery indicated that LB-100 could compel cancer cells to shed their malignant properties, proposing a new therapeutic strategy. Another study published in EMBO revealed how LB-100 prompts cancer cells to generate neoantigens, making them more susceptible to immunotherapy.

LIXTE Biotechnology Holdings, Inc. remains at the forefront of cancer drug development, focusing on novel targets for therapeutic advancement. The company's lead clinical PP2A inhibitor, LB-100, has demonstrated promising tolerance and anti-cancer activity in patients, supported by extensive preclinical data. LB-100 is part of a groundbreaking effort in the emerging field of cancer biology known as activation lethality, heralding a new treatment paradigm. This approach, unique to LIXTE, has no current competitors and is protected by a robust patent portfolio. Proof-of-concept clinical trials are in progress, underscoring LIXTE's pioneering role in transforming cancer treatment.

In conclusion, LIXTE Biotechnology Holdings is making substantial progress in the development of innovative cancer therapies. Through strategic collaborations, clinical trials, and intellectual property advancements, LIXTE continues to enhance its impact in the medical field, aiming to improve outcomes for cancer patients worldwide.